Aurinia Pharmaceuticals Inc.

AUPH Healthcare · Biotechnology www.auriniapharma.com
$15.22
Mkt Cap 1.96B
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States a…

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.

—
/100 Overall
Calculating score…
Running full analysis
Ready to value this company?
Run a full DCF model with Monte Carlo simulation.
Run DCF Valuation →
📊 Key Metrics
Loading full analysis…
REVENUE TTM
$298.3M
57.8% CAGR
FCF TTM
$165.5M
55.5% margin
Running full 6-factor analysis…